Skip to content
Lower risk Drug recall · FDA · Published October 20, 2017

Pfizer Zoloft 25mg Tablets Recall: Weight Variations Risk Sub/Super Potency

Pfizer recalls Zoloft 25mg tablets due to weight variations causing subpotent or superpotent tablets. This may affect prescription medication safety. Check your NDC 0049-4960-30 lot S84026.

🇺🇸 FDA recall #D-0151-2018DrugPfizer ›
Take action

Contact the company

Recalling firmPfizer Inc.235 E 42nd St · New York, NY 10017-5703
✎ GovInfoNow plain-language explainer

What happened, in plain English

Pfizer is recalling Zoloft 25mg tablets because some tablets may have weight variations that make them too weak or too strong. This could lead to incorrect dosing and potential health risks if taken without proper medical guidance. Read more at govinfonow.com/recall/41122-pfizer-zoloft-25mg-tablets-recall-weight-variations-risk-sub-super.

Source Summary by GovInfoNow · govinfonow.com/recall/41122-pfizer-zoloft-25mg-tablets-recall-weight-variations-risk-sub-super · Updated October 7, 2026 · FDA enforcement record: FDA #D-0151-2018

Cite this page

“Pfizer Zoloft 25mg Tablets Recall: Weight Variations Risk Sub/Super Potency.” GovInfoNow, updated October 7, 2026. https://govinfonow.com/recall/41122-pfizer-zoloft-25mg-tablets-recall-weight-variations-risk-sub-super. Based on FDA recall #D-0151-2018 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0151-2018%22&limit=1).

Why it’s dangerous

Weight variations in the tablets can cause some doses to be too weak (subpotent) or too strong (superpotent). This means patients might receive incorrect medication amounts, potentially leading to ineffective treatment or adverse effects.

Who’s affected

Prescription patients who have received the specific Zoloft 25mg 30-count bottle with NDC 0049-4960-30 lot S84026. Those with a history of severe side effects from SSRIs may be at higher risk.

How to tell if you have this one

Check for the Zoloft 25mg 30-count bottle with NDC code 0049-4960-30 and lot number S84026. This product was distributed by Pfizer's Roerig division and sold through prescription only.

  • Brand
    Pfizer
  • Category
    Drug
FDA recall event · 2 products

All 2 products in this recall

FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.

  • Status
    Terminated
  • Distribution
    Nationwide in the USA
Recall numberProduct, codes & lotsQuantityClassNDC
D-0150-2018diphenoxylate hydrochloride and atropine sulfate tablets, USP, 2.5 mg/0.025 mg, a) 100-count bottle (NDC 59762-1061-1), b) 1000-count bottle (NDC 59762-1061-2), Rx Only, Distributed by: Greenstone LLC. Peapack, NJ 07977; Lots: a) R83962, R93347, R93348, R93349, R93350, R93351, R93352, Exp. 2021 OCT 31; S57831, S57832, S57834, Exp. 2021 NOV 30 b) R93356, R93357, R93358, R97310, Exp. 2021 OCT 31.183437 bottlesClass I59762-1061-1, 59762-1061-2
D-0151-2018Zoloft (sertraline HCl) tablets 25 mg* 30-count bottle, Rx only, Distributed by Roerig Division of Pfizer Inc., NY, NY, 10017 NDC 0049-4960-30; Lot: S840261972 bottlesClass II—
Based on the official FDA remedy

What to do — step by step

  1. Check Your Medication

    Verify if your Zoloft tablets have the NDC 0049-4960-30 and lot number S84026.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 2.6 years after the firm started it.

1. Firm started the recall: Oct 20, 201712. FDA classified it Class II: Jan 4, 201823. Published in FDA’s Enforcement Report: Jan 10, 201834. FDA terminated the recall: Jun 2, 2020420172020
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0151-2018 (October 20, 2017) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0151-2018 to see it in context.
  • Plain-language summary written by qwen3:4b on October 7, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA